RecruitingPhase 1NCT07439796
A Study of ORN252 in Healthy Participants
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORN252 in Healthy Participants
Sponsor
Orna Therapeutics, Inc.
Enrollment
20 participants
Start Date
Mar 16, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria2
- Male and female participants who are healthy as determined by the Investigator based on review of medical history, physical examination, and laboratory tests
- Participant is willing and able to comply with study visits and other protocol requirements
Exclusion Criteria2
- Clinically significant history or presence of organ dysfunction
- Use of any investigational product within 3 months, or 5 half-lives, whichever longer
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALORN252
ORN252 is a lipid nanoparticle encapsulating a circular RNA encoding an anti-CD19 CAR protein.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07439796